Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation

Published:2022-05-27 Issue:1 Volume:27 Page:620-628
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Teshigawara-Tanabe Haruka¹²^ORCID,Hagihara Maki²^ORCID,Aoki Jun³,Koyama Satoshi²,Takahashi Hiroyuki²^ORCID,Nakajima Yuki²,Kunimoto Hiroyoshi¹²,Tachibana Takayoshi⁴^ORCID,Miyazaki Takuya²,Matsumoto Kenji²,Tanaka Masatsugu⁴^ORCID,Yamazaki Etsuko⁵,Fujisawa Shin³,Kanamori Heiwa⁴,Taguri Masataka⁶^ORCID,Nakajima Hideaki¹²^ORCID

Affiliation:

1. Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan

2. Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan

3. Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

4. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

5. Department of Laboratory Medicine, Yokohama City University Hospital, Yokohama, Japan

6. Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2022.2052601

Reference20 articles.

1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

2. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

3. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

4. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO)

5. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome